反应详情

Trans-methyl 2-(3-fluoro-4-(trifluoromethyl)benzyl)-4-(3-oxo-2,3-dihydroisoxazol-5-yl)-piperidine-1-carboxylate (0.224 g, 0.56 mmol) was dissolved in hydrogen bromide (33% in acetic acid, 5 mL, 71.37 mmol) and stirred at room temperature for 1 week. The solvents were evaporated and the residue purified by preparative HPLC (Instrument: FractionLynx III, Mobilphase: gradient 5-95% MeCN in 0.2% NH3, pH 10, Column: Xbridge Prep C18 5 μm OBD 19*150 mm) to yield 5-(trans-2-(3-fluoro-4-(trifluoromethyl)benzyl)piperidin-4-yl)isoxazol-3(2H)-one (160 mg, 83%). 1H NMR (600 MHz, dmso) δ 1.48 (ddd, 1H), 1.63-1.81 (m, 3H), 2.51-2.59 (m, 1H), 2.70-2.82 (m, 3H), 2.88-2.95 (m, 1H), 3.07-3.14 (m, 1H), 5.72 (s, 1H), 7.21 (d, 1H), 7.33 (d, 1H), 7.63 (t, 1H). HRMS Calculated for [C16H16F4N2O2+H]+: 345.1226. Found: 345.1241

1. customThe solvents were evaporated
2. customthe residue purified by preparative HPLC (Instrument: FractionLynx III, Mobilphase: gradient 5-95% MeCN in 0.2% NH3, pH 10, Column: Xbridge Prep C18 5 μm OBD 19*150 mm)